Coronary heart disease (CHD) affects 17 million people in the United States and accounts for over a million hospital stays each year. Technological advances, especially in genetics and genomics, have changed our understanding of the risk factors for developing CHD. The purpose of this article is to review low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), and risk of CHD. The article focuses on five topics: (1) a description of lipoprotein classes, normal lipoprotein metabolism, and the biological mechanism of atherosclerosis; (2) a review of selected epidemiologic and clinical trial studies examining the associations between elevated LDL-C and apo B with CHD; (3) a brief review of the familial forms of hyperlipidemia; (4) a description of variants in genes that have been associated with higher LDL-C levels in candidate gene studies and genome-wide association studies (GWAS); and (5) nursing implications, including a discussion on how genetic tests are evaluated and the current clinical utility and validity of genetic tests for CHD.
AbifadelM.RabesJ. P.DevillersM.MunnichA.ErlichD.JunienC.BoileauC. (2009). Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Human Mutation, 30, 520–529. doi:10.1002/humu.20882
2.
Adult Treatment Panel III. (2002). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults final report. Circulation, 106, 3143–3421. Retrieved fromhttp://circ.ahajournals.org/cgi/content/full/106/25/3143
3.
APOA5—apolipoprotein A-V. (n.d.). Retrieved July 5, 2011, from the U. S. National Library of Medicine’s Genetics Home Reference website: http://ghr.nlm.nih.gov/gene/APOA5
4.
ATP-binding cassette, subfamily G, member 5. (2011) Retrieved from Online Mendelian Inheritance in Man athttp://omim.org/entry/605459
5.
AulchenkoY. S.RipattiS.LindqvistI.BoomsmaD.HeidI. M.PramstallerP. P.PeltonenL. (2009). Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nature Genetics, 41, 47–55. doi:10.1038/ng.269
6.
AustinM. A.BrunzellJ. D.FitchW. L.KraussR. M. (1990). Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis, 10(4), 520–530. doi:10.1161/?01.ATV.10.4.520
7.
AustinM. A.HutterC. M.ZimmernR. L.HumphriesS. E. (2004). Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review. American Journal of Epidemiology, 160, 407–420. doi:10.1093/aje/kwh236. doi:10.1093/aje/kwh236
8.
AustinM. A.McKnightB.EdwardsK. L.BradleyC. M.McNeelyM. J.PsatyB. M.MotulskyA. G. (2000). Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation, 101, 2777–2782. doi:10.1161/01.CIR.101.24.2777
9.
BennM. (2009). Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. Atherosclerosis, 206, 17–30. doi:10.1016/j.atherosclerosis.2009.01.004
10.
BennM.NordestgaardB. G.JensenG. B.Tybjaerg-HansenA. (2007). Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 661–670. doi:10.1161/01.ATV.0000255580.73689.8e
11.
BennetA.Di AngelantonioE.ErqouS.EiriksdottirG.SigurdssonG.WoodwardM.GudnasonV. (2008). Lipoprotein(a) levels and risk of future coronary heart disease: Large-scale prospective data. Archives of Internal Medicine, 168, 598–608. doi:10.1001/archinte.168.6.598
12.
BerensonG. S.SrinivasanS. R.BaoW.NewmanW. P.3rdTracyR. E.WattigneyW. A. (1998). Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. New England Journal of Medicine, 338, 1650–1656.
13.
BhatiaS. S.DaviesR. W.McPhersonR. (2009). Relationship of rs4420638 in the APOE/C1/C4/C2 locus to coronary artery disease. Paper presented at the 59th Annual Meeting of the American Society of Human Genetics, Honolulu, HI. Abstract retrieved fromhttp://www.ashg.org/2009meeting/abstracts/fulltext/f10745.htm
14.
BurkeW.PinskyL. E.PressN. A. (2001). Categorizing genetic tests to identify their ethical, legal, and social implications. American Journal of Medical Genetics, 106, 233–240. doi:10.1002/ajmg.10011
15.
BurkeW.ZimmernR. L. (2004). Ensuring the appropriate use of genetic tests. Nature Reviews Genetics, 5, 955–959. doi:10.1038/nrg1495
16.
BurkhardtR.KennyE. E.LoweJ. K.BirkelandA.JosowitzR.NoelM.BreslowJ. L. (2008). Common SNPs in HMGCR in Micronesians and Whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 2078–2084. doi:10.1161/ATVBAHA.108.172288
ChienK. L.HsuH. C.SuT. C.ChenM. F.LeeY. T.HuF. B. (2007). Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. Journal of Lipid Research, 48, 2499–2505. doi:10.1194/jlr.M700213-JLR200
19.
ContoisJ. H.McConnellJ. P.SethiA. A.CsakoG.DevarajS.HoefnerD. M. & WarnickG. R. (2009). Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clinical Chemistry, 55, 407–419. doi:10.1373/clinchem.2008.118356
20.
DefescheJ. C.SchuurmanE. J.KlaaijsenL. N.KhooK. L.WiegmanA.StalenhoefA. F. (2008). Silent exonic mutations in the low-density lipoprotein receptor gene that cause familial hypercholesterolemia by affecting mRNA splicing. Clinical Genetics, 73, 573–578. doi:10.1111/j.1399-0004.2008.00999.x
21.
DelaneyJ. A.DaskalopoulouS. S.BrophyJ. M.SteeleR. J.OpatrnyL.SuissaS. (2007). Lifestyle variables and the risk of myocardial infarction in the general practice research database. BMC Cardiovascular Disorders, 7, 38. doi:10.1186/1471-2261-7-38
22.
DreonD. M.FernstromH. A.MillerB.KraussR. M. (1994). Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB Journal, 8, 121–126. Retrieved fromhttp://www.fasebj.org/content/8/1/121.long
23.
GenestJ. (2003). Lipoprotein disorders and cardiovascular risk. Journal of Inherited Metabolic Disease, 26, 267–287. doi:10.1023/A:1024449603891
24.
GoldsteinJ. L.BrownM. S. (2009). History of discovery: The LDL receptor. Arteriosclerosis, Thrombosis, and Vascular Biology, 29, 431–438. doi:10.1161/ATVBAHA.108.179564
25.
GrundyS. M. (1990). Cholesterol and atherosclerosis: Diagnosis and treatment. Philadelphia, PA: J. B. Lippincott Company.
26.
Heart Protection Study Collaborative Group. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, 7–22. doi:10.1016/S0140-6736(02)09327-3
27.
HegeleR. A. (2009). Plasma lipoproteins: Genetic influences and clinical implications. Nature Reviews Genetics, 10, 109–121. doi:10.1038/nrg2481
28.
HindorffL. A.MacArthurJ.(European Bioinformatics Institute), WiseA.JunkinsH. A.HallP. N., Klemm, A. K.ManolioT. A. (n.d.). A catalog of published genome-wide association studies. Retrieved May 28, 2011, from the National Human Genome Research Institute website: www.genome.gov/gwastudies
29.
HiuraY.TabaraY.KokuboY.OkamuraT.GotoY.NonogiH.IwaiN. (2010). Association of the functional variant in the 3-hydroxy-3-methylglutaryl-coenzyme a reductase gene with low-density lipoprotein-cholesterol in Japanese. Circulation Journal, 74, 518–522. doi:10.1253/circj.CJ-09-0790
30.
HolmanR. L. (1961). Atherosclerosis—A pediatric nutrition problem?American Journal of Clinical Nutrition, 9, 565–569.
31.
HolmeI.HostmarkA. T.AndersonS. A. (2007). ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men. Results from the 1-year randomized Oslo Diet and Exercise Study. Journal of Internal Medicine, 262, 235–243. doi:10.1111/j.1365-2796.2007.01806.x
32.
Hyperlipidemia, Familial Combined. (2007). Retrieved from Online Mendelian Inheritance in Man athttp://omim.org/entry/144250
33.
InsullW.Jr. (2009). The pathology of atherosclerosis: Plaque development and plaque responses to medical treatment. American Journal of Medicine, 122, S3–S14. doi:10.1016/j.amjmed.2008.10.013
34.
KathiresanS.MelanderO.AnevskiD.GuiducciC.BurttN. P.RoosC.Orho-MelanderM. (2008). Polymorphisms associated with cholesterol and risk of cardiovascular events. New England Journal of Medicine, 358, 1240–1249. doi:10.1056/NEJMoa0706728
35.
KathiresanS.WillerC. J.PelosoG. M.DemissieS.MusunuruK.SchadtE. E.CupplesL. A. (2009). Common variants at 30 loci contribute to polygenic dyslipidemia. Nature Genetics, 41, 56–65. doi:10.1038/ng.291
36.
Ken-DrorG.TalmudP. J.HumphriesS. E.DrenosF. (2010). APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men. Molecular Medicine, 16, 389–399. doi:10.2119/molmed.2010.00044
37.
KolovouG. D.AnagnostopoulouK. K.KostakouP. M.BilianouH.MikhailidisD. P. (2009). Primary and secondary hypertriglyceridaemia. Current Drug Targets, 10, 336–343.
38.
KulloI. J.CooperL. T. (2010). Early identification of cardiovascular risk using genomics and proteomics. Nature Reviews Cardiology, 7, 309–317. doi:10.1038/nrcardio.2010.53
LDLRAP1—low density lipoprotein receptor adaptor protein 1. (2007). Retrieved from the U. S. National Library of Medicine’s Genetics Home Reference website: http://ghr.nlm.nih.gov/gene/LDLRAP1
41.
LeighS. E.FosterA. H.WhittallR. A.HubbartC. S.HumphriesS. E. (2008). Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Annals of Human Genetics, 72, 485–498. doi:10.1111/j.1469-1809.2008.00436.x
42.
Lloyd-JonesD.AdamsR. J.BrownT. M.CarnethonM.DaiS.De SimoneG.Wylie-RosettJ. (2010). Heart disease and stroke statistics–2010 update: A report from the American Heart Association. Circulation, 121, e46–e215. doi:10.1161/CIRCULATIONAHA.109.192667
43.
LusisA. J.PajukantaP. (2008). A treasure trove for lipoprotein biology. Nature Genetics, 40, 129–130. doi:10.1038/ng0208-129
MahleyR. W.HuangY.RallS. C, Jr. (1999). Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. Journal of Lipid Research, 40, 1933–1949. Retrieved fromhttp://www.jlr.org/content/40/11/1933.long
46.
ManolioT. A. (2010). Genomewide association studies and assessment of the risk of disease. New England Journal of Medicine, 363, 166–176. doi:10.1056/NEJMra0905980
47.
ManolioT. A.CollinsF. S.CoxN. J.GoldsteinD. B.HindorffL. A.HunterD. J.VisscherP. M. (2009). Finding the missing heritability of complex diseases. Nature, 461, 747–753. doi:10.1038/nature08494
48.
MarcovinaS. M.KoschinskyM. L. (1998). Lipoprotein(a) as a risk factor for coronary artery disease. American Journal of Cardiology, 82, 57U–66U; Discussion 86U. doi:10.1016/S0002-9149(98)00954-0
49.
MatthanN. R.WeltyF. K.BarrettH. R.HarauszC.DolnikowskiG. G.ParksJ. S.LichtensteinA. H. (2004). Dietary hydrogenated fat increase high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1092–1097. doi:10.1161/01.ATV.0000128410.23161.be
McGillH. C.JrMcMahanC. A.GiddingS. S. (2008). Preventing heart disease in the 21st century: Implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation, 117, 1216–1227. doi:10.1161/CIRCULATIONAHA.107.717033
52.
McPhersonE. (2006). Genetic diagnosis and testing in clinical practice. Clinical Medicine & Research, 4, 123–129. doi:10.3121/cmr.4.2.123
53.
NakamuraH.ArakawaK.ItakuraH.KitabatakeA.GotoY.ToyotaT.OhashiY. (2006). Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet, 368, 1155–1163. doi:10.1016/S0140-6736(06)69472-5
54.
NakayamaK.BayasgalanT.YamanakaK.KumadaM.GotohT.UtsumiN.IwamotoS. (2009). Large scale replication analysis of loci associated with lipid concentrations in a Japanese population. Journal of Medical Genetics, 46, 370–374. doi:10.1136/jmg.2008.064063
55.
NatarajanP.RayK. K.CannonC. P. (2010). High-density lipoprotein and coronary heart disease. Journal of the American College of Cardiology, 55, 1283–1299. doi:10.1016/j.jacc.2010.01.008
National Center for Biotechnology Information. (n.d.). Submission and assignment of submitted SNP(ss)/refSNP(rs) numbers. Retrieved December 15, 2011, fromhttp://www.ncbi.nlm.nih.gov/books/NBK44391/
58.
NaukkarinenJ.EhnholmC.PeltonenL. (2006). Genetics of familial combined hyperlipidemia. Current Opinion in Lipidology, 17, 285–290. doi:10.1097/01.mol.0000226121.27931.3f
59.
NordestgaardB. G.ChapmanM. J.RayK.BorenJ.AndreottiF.WattsG. F.Tybjærg-HansenA. (2010). Lipoprotein(a) as a cardiovascular risk factor: Current status. European Heart Journal, 31, 2844–2853. doi:10.1093/eurheartj/ehq386
60.
PearsonT. A.ManolioT. A. (2008). How to interpret a genome-wide association study. Journal of the American Medical Association, 299, 1335–1344. doi:10.1001/jama.299.11.1335
61.
PekkanenJ.LinnS.HeissG.SuchindranC. M.LeonA.RifkindB. M.TryolerH. A. (1990). Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. New England Journal of Medicine, 322, 1700–1707. Retrieved fromhttp://www.nejm.org/doi/full/10.1056/NEJM199006143222403
PlaisierC. L.HorvathS.Huertas-VazquezA.Cruz-BautistaI.HerreraM. F.Tusie-LunaT.PajukantaP. (2009). A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia. PLoS Genetics, 5, e1000642. doi:10.1371/journal.pgen.1000642
64.
ReichD. E.LanderE. S. (2001). On the allelic spectrum of human disease. Trends in Genetics, 17, 502–510. doi:10.1016/S0168-9525(01)02410-6
65.
RidkerP. M.RifaiN.CookN. R.BradwinG.BuringJ. E. (2005). Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. Journal of the American Medical Association, 294, 326–333. doi:10.1001/jama.294.3.326
66.
RussoC. A.AndrewsR. M. (2006, September). The national hospital bill: The most expensive conditions, by payer, 2004(HCUP Statistical Brief no. 13). Rockville, MD: Agency for Healthcare Research and Quality. Retrieved fromhttp://www.hcup-us.ahrq.gov/reports/statbriefs/sb13.pdf
67.
SabattiC.ServiceS. K.HartikainenA. L.PoutaA.RipattiS.BrodskyJ.PeltonenL. (2009). Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nature Genetics, 41, 35–46. doi:10.1038/ng.271
68.
SáezM. E.González-PérezA.Martínez-LarradM. T.GayánJ.RealL. M.Serrano-RíosM. & RuizA. (2010). WWOX gene is associated with HDL cholesterol and triglyceride levels. BMC Medical Genetics, 11, 148. doi:10.1186/1471-2350-11-148
69.
SchaeferE. J. (2002). Lipoproteins, nutrition, and heart disease. American Journal of Clinical Nutrition75, 191–212. Retrieved fromhttp://www.ajcn.org/content/75/2/191.full
70.
Scandinavian Simvastatin Survival Study Group. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4 S). Lancet, 344, 1383–1389. doi:10.1016/S0140-6736(94)90566-5
71.
SealN. (2011). Introduction to genetics and childhood obesity: Relevance to nursing practice. Biological Research for Nursing, 13, 61–69. doi:10.1177/1099800410381424
72.
SeverP. S.DahlofB.PoulterN. R.WedelH.BeeversG.CaulfieldM.OstergrenJ. (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet, 361, 1149–1158. doi:10.1016/S0140-6736(03)12948-0
73.
ShepherdJ.BlauwG. J.MurphyM. B.BollenE. L.BuckleyB. M.CobbeS. M.WestendorpR. G. (2002). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet, 360, 1623–1630. doi:10.1016/S0140-6736(02)11600-X
74.
ShouldersC. C.JonesE. L.NaoumovaR. P. (2004). Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Human Molecular Genetics, 13, R149–R160. doi:10.1093/hmg/ddh069
75.
SlatkinM. (2008). Linkage disequilibrium—Uunderstanding the evolutionary past and mapping the medical future. Nature Reviews Genetics, 9, 477–485. doi:10.1038/nrg2361
76.
StamlerJ.StamlerR.NeatonJ. D.WentworthD.DaviglusM. L.GarsideD.GreenlandP. (1999). Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: Findings for 5 large cohorts of young adult and middle-aged men and women. Journal of the American Medical Association, 282, 2012–2018. doi:10.1001/jama.282.21.2012
77.
St-PierreA. C.CantinB.DagenaisG. R.DespresJ. P.LamarcheB. (2006). Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. American Journal of Cardiology, 97, 997–1001. doi:10.1016/j.amjcard.2005.10.060
78.
SurmiB. K.HastyA. H. (2010). The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vascular Pharmacology, 52, 27–36. doi:10.1016/j.vph.2009.12.004
79.
TaborH. K.RischN. J.MyersR. M. (2002). Candidate-gene approaches for studying complex genetic traits: Practical considerations. Nature Reviews Genetics, 3, 391–397. doi:10.1038/nrg796
80.
TaiE. S.SimX. L.OngT. H.WongT. Y.SawS. M.AungT.SeielstadM. (2009). Polymorphisms at newly identified lipid-associated loci are associated with blood lipids and cardiovascular disease in an Asian Malay population. Journal of Lipid Research, 50, 514–520. doi:10.1194/jlr.M800456-JLR200
81.
ToborekM.LeeY. W.GarridoR.KaiserS.HennigB. (2002). Unsaturated fatty acids selectively induce an inflammatory environment in human endothelial cells. American Journal of Clinical Nutrition, 75, 119–125. Retrieved fromhttp://www.ajcn.org/content/75/1/119.full
VisscherP. M.MontgomeryG. W. (2009). Genome-wide association studies and human disease: From trickle to flood. Journal of the American Medical Association, 302, 2028–2029. doi:10.1001/jama.2009.1643
84.
VolpatoS.VignaG. B.McDermottM. M.CavalieriM.MaraldiC.LauretaniF.FerrucciL. (2010). Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study). American Journal of Cardiology, 105, 1825–1830. doi:10.1016/j.amjcard.2010.01.370
85.
WaterworthD. M.RickettsS. L.SongK.ChenL.ZhaoJ. H.RipattiS.SandhuM. S. (2010). Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arteriosclerosis, Thrombosis, Vascular Biology, 30, 2264–2276. doi:10.1161/ATVBAHA.109.201020
86.
WillerC. J.SannaS.JacksonA. U.ScuteriA.BonnycastleL. L.ClarkeR.AbecasisG. R. (2008). Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nature Genetics, 40, 161–169. doi:10.1038/ng.76
87.
WilsonP. W.D’AgostinoR. B.LevyD.BelangerA. M.SilbershatzH.KannelW. B. (1998). Prediction of coronary heart disease using risk factor categories. Circulation, 97, 1837–1847. Retrieved fromhttp://circ.ahajournals.org/cgi/content/full/97/18/1837
88.
WongN. D.WilsonP. W.KannelW. B. (1991). Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham Study. Annals of Internal Medicine, 115, 687–693.
